Fenye Liu

Dr. Fenye Liu

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
SYshudong yu
shudong yu
FLFenye Liu
Fenye Liu
ZCZhixin Cheng
Zhixin Cheng
QWQirong Wang
Qirong Wang
Increasing recent evidence has implicated osteoporosis as a risk factor for benign paroxysmal positional vertigo (BPPV). We conducted a systematic review to examine the association between osteoporosis and BPPV.

4 July 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SLShuo Liu
Shuo Liu
YWYuchen Wan
Yuchen Wan
ZHZiyu Hu
Ziyu Hu
ZWZhixue Wang
Zhixue Wang
FLFenye Liu
Fenye Liu
Background: Nephrotic syndrome (NS) can occur as a paraneoplastic disorder in association with various types of carcinoma. However, paraneoplastic nephrotic syndrome (PNS) is often misdiagnosed as idiopathic nephrotic syndrome or as an adverse effect of oncology treatment, leading to delayed diagnosis and suboptimal treatment. The characteristics of NS associated with solid malignancies are not yet elucidated. We systematically summarized the clinical data for 128 cases of NS combined with solid malignancies with the aim of informing the clinical management of PNS. Methods: We searched the PubMed database for articles published from the date of inception through to October 2023 using the following keywords: “cancer” or “malignant neoplasms” or “neoplasia” or “tumors” and “nephrotic syndrome”, “nephrotic” or “syndrome, nephrotic”. All data were extracted from case reports and case series, and the extraction included a method for identifying individual-level patient data. Results: A literature search yielded 105 cases of PNS and 23 of NS induced by cancer therapy. The median age at diagnosis was 60 years, with a male to female ratio of 1.8:1. In patients with PNS, manifestations of NS occurred before, concomitantly with, or after diagnosis of the tumor (in 36%, 30%, and 34% of cases, respectively). Membranous nephropathy (49%) was the most prevalent renal pathology and found particularly in patients with lung, colorectal, or breast carcinoma. Regardless of whether treatment was for cancer alone or in combination with NS, the likelihood of remission was high. Conclusion: The pathological type of NS may be associated with specific malignancies in patients with PNS. Prompt identification of PNS coupled with suitable therapeutic intervention has a significant impact on the outcome for patients.

31 December 2007 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
FLFenye Liu
Fenye Liu
JZJidong Zhang
Jidong Zhang
SYShudong Yu
Shudong Yu
RWRong Wang
Rong Wang
BWBo Wang
Bo Wang
GLGuilin Liu
Guilin Liu

5 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YWYuchen Wan
Yuchen Wan
ZWZhixue Wang
Zhixue Wang
NYNing Yang
Ning Yang
FLFenye Liu
Fenye Liu
Background: With significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the survival of a broad spectrum of tumors. However, little information is available when it comes to the efficacy, resistance, and underlying mechanisms of ICIs.Case Presentation: A 67-year-old woman was diagnosed with pulmonary sarcomatoid carcinoma (PSC) with a history of hepatocellular carcinoma (HCC) and viral hepatitis B. Following the lack of response to systemic chemotherapy, she was treated with camrelizumab, an anti-programmed cell death protein 1 monoclonal antibody, in combination with chemotherapy, and a partial response was obtained both in PSC and HCC. After a course of 9-month treatment, the PSC lesion shrank still, while HCC was evaluated as a progressive disease with an increase in the diameter of liver neoplasm, elevated alpha-fetoprotein, and enlarged abdominal lymph nodes. Then, with the addition of radiotherapy for abdominal metastasis, the lung lesion was continuously shrinking. In the meantime, the liver neoplasm and abdominal lymph nodes showed no significant enlargement.Conclusion: Camrelizumab combination therapy could consistently benefit the MPM patients with PSC and HCC, which may be a promising option for patients with MPMs.

5 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XDXiucheng Duan
Xiucheng Duan
LZLiyuan Zhang
Liyuan Zhang
FLFenye Liu
Fenye Liu
Objective: Quercetin, a ubiquitous natural flavonoid present in numerous medicinal plants and foods, has been widely recognized for its various bioactive properties. However, despite its potential, the preclinical animal studies evaluating its therapeutic efficacy in colorectal cancer (CRC) remain inadequate, and the existing clinical research in this area is still limited in quantity. These deficiencies hinder the practical application of quercetin in the treatment of colorectal cancer.Methods: Our comprehensive review involved systematically searching major databases—including PubMed, Web of Science, and Embase—up to April 2025 for relevant preclinical studies. The SYRCLE risk of bias tool was employed by researchers to evaluate each entry. Subsequently, data analysis was conducted using the statistical software Review Manager 5.4.Results: The results of our meta-analysis showed that quercetin treatment not only significantly reduced the incidence of CRC (SMD-1.22, 95% CI: −0.26 to −0.38, p = 0.004), but also alleviated inflammation and oxidative stress compared with the control group. Quercetin treatment effectively improved the degree of crypt lesions (SMD-1.40, 95%CI: −2.53 to −0.26, p = 0.02) and alleviated precancerous lesions in the animal model of CRC. In terms of tumor cell proliferation, quercetin had a significant inhibitory effect on cell proliferation during treatment, as determined by PCNA analysis (SMD -8.22, 95% CI: −10.48 to −5.95, p < 0.00001). Quercetin may promote apoptosis during treatment, but this hypothesis has not been supported.Conclusion: Our study indicates that quercetin exerts beneficial effects across multiple facets of CRC treatment. Nonetheless, precise evaluation of quercetin’s impact on colorectal cancer demands further high-quality, large-scale animal and human studies to confirm our findings.Systematic Review Registration: https://inplasy.com, identifier INPLASY202550014.

4 January 2008 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
FLFenye Liu
Fenye Liu
JZJiDong Zhang
JiDong Zhang
SYShuDong Yu
ShuDong Yu
RWRong Wang
Rong Wang
BWBo Wang
Bo Wang
GLGuilin Liu
Guilin Liu